Concepedia

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung‐Bae Kim, Toshimi Takano, Seock‐Ah Im, Giuliano Borges, João Paulo da Silveira Nogueira Lima, Sercan Aksoy, Joaquín Gavilá Gregori, Michelino De Laurentiis,

The Lancet · 2023 · 345 citations · 22 references

DOIFull text

Open access

Concepts

References

22

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text

, , +14

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text

, , +14

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

, , +12

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Journal of Clinical Oncology · 2018 · 2.5K citations · Full text

, , +15